Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Row1 Inc. dba Regenative Labs
WARNING LETTER
•Row1 Inc. dba Regenative Labs•March 30, 2022

Row1 Inc. dba Regenative Labs – FDA Warning Letter, Mar 30, 2022

Record Details

On June 21, 2023, the FDA issued a Warning Letter to Row1, Inc. (dba Regenative Labs) following an inspection from March 21-30, 2022. The inspection documented the manufacture and distribution of human umbilical cord-derived cellular products (ProText™, CoreText™, CryoText™ Pro, CryoText™ Plus, SecreText™, and SecreText™ Pro), intended for injection and purporting to be sterile.

The FDA determined these products are drugs and biological products, not solely HCT/Ps, because they fail to meet the homologous use and minimal manipulation criteria under 21 CFR 1271.10(a). Consequently, they require an approved Biologics License Application (BLA) or an Investigational New Drug (IND) application, neither of which Regenative Labs possesses.

The letter also cited significant Current Good Manufacturing Practice (CGMP) deviations for over (b)(4) vials manufactured between February 2020 and March 2022. Violations include: 1. Failure to validate aseptic processes and establish appropriate environmental monitoring procedures (e.g., high action limits for microbiological monitoring, no non-viable particulate monitoring, inadequate personnel practices). 2. Failure to validate manufacturing processes for identity, strength, quality, and purity. 3. Failure to establish a written stability testing program to support the assigned five

Company
Row1 Inc. dba Regenative Labs
Inspection date
March 30, 2022
Product type
Biologics
Office
Division of Biological Products Operations I
People
  • Michael W. Roosevelt (Program Division Director)
  • Amy Graf
View Company Profile

ID · 5af50e5b-e95b-4c48-9cf7-83582e155755

Violation Codes10
21 U.S.C. 321(g)21 CFR 1271.3(d)21 CFR 127121 CFR 1271.10(a)21 CFR 1271.1521 CFR 1271.10(a)(2)21 CFR 1271.3(c)21 CFR 1271.10(a)(1)21 CFR 1271.3(f)(1)21 U.S.C. 355(i)

Full citation text and observation details available on the Dashboard.

Other documents for Row1 Inc. dba Regenative Labs
  • 483 - 2022-03-30March 30, 2022

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Row1 Inc. dba Regenative Labs
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.